<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:13pt Times New Roman, serif; }
 .font4 { font:19pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font4">J.P. Morgan</span></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.2hao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.2hao@jpmorgan.com</span></a></p>
<p><span class="font3">As of now, Fosun has 172 pipeline drugs, generic drugs, biosimilars and vaccine projects. Fosun has also applied for 89 patents, including 6 U.S. patent applications, 4 European patent applications, 2 Japanese patent applications and 3 PCT applications, in respect of its pharmaceutical manufacturing and R&amp;D segment. The pharmaceutical manufacturing and R&amp;D segment of the Group obtained 15 licensed patents, including 9 invention patents (including 1 U.S. patent) in 2015. 13 APIs of Fosun also received GMP certifications from the U.S. FDA, EU, Ministry of Health, Labor and Welfare of Japan and Federal Ministry of Health of Germany.</span></p>
<p><span class="font2" style="font-weight:bold;">Table 5: Fosun’s R&amp;D Platform</span></p>
<p><span class="font1" style="font-weight:bold;">Features of R&amp;D platform</span></p>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Monoclonal Antibody Bio similar Drugs</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Small Molecular innovative Drugs</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Generic Drugs with High Barriers-To-Entry</span></p></td></tr>
<tr><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;First in China to adopt advanced single-use technology for production, laying foundation for production cost control</span></p></li>
<li>
<p><span class="font1" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;World-class QA and QC control systems to ensure product quality</span></p></li>
<li>
<p><span class="font1" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;First in China to obtain clinical trial approval under the guideline of biosimilars</span></p></li></ul></td><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Structure-based drug design (SBDD) platfoim adopted.</span></p></li></ul>
<p><span class="font1" style="font-weight:bold;">Such technology significantly improved the accuracy of new drug discovery and reduced the R&amp;D cost for new drugs</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;24-hour R&amp;D in laboratories in both China and the U.S.</span></p></li></ul>
<p><span class="font1" style="font-weight:bold;">improves R&amp;D efficiency</span></p></td><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font1" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;R&amp;D of hard-to-copy generic drugs oriented by clinical requirements and market demand</span></p></li>
<li>
<p><span class="font1" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Taking advantage of the leading position of branded generic drugs to power the organic growth of the company</span></p></li></ul></td></tr>
</table>
<p><span class="font1">Source: Company dale, J.P. Morgan</span></p>
<p><span class="font0" style="font-weight:bold;">10</span></p>
</body>
</html>